• The stock is up 4.2% at $28.04 today, extending a multi-day rebound.
  • This follows recent participation in the Goldman Sachs 47th Annual Global Healthcare Conference where Ultragenyx highlighted its gene therapy pipeline and regulatory tailwinds, alongside a US$81.53 million ESOP shelf registration filed on June 16, 2026.
  • Additionally, new institutional investments from Eversept Partners LP and Ishara Investments LP were reported on June 18, 2026.